Effects of dapagliflozin in Asian patients with heart failure and reduced ejection fraction in DAPA-HF

Docherty, K. F. et al. (2022) Effects of dapagliflozin in Asian patients with heart failure and reduced ejection fraction in DAPA-HF. JACC: Asia, 2(2), pp. 139-153. (doi: 10.1016/j.jacasi.2022.02.004) (PMID:36339117) (PMCID:PMC9627879)

[img] Text
268373.pdf - Published Version
Available under License Creative Commons Attribution.



Background: Patients with heart failure with reduced ejection fraction (HFrEF) in Asia exhibit many differences from those in other parts of the world. Objectives: This study sought to investigate the efficacy and safety of dapagliflozin, compared with placebo, in HFrEF patients in Asia, compared with those elsewhere, enrolled in the DAPA-HF (Dapagliflozin and Prevention of Adverse-outcomes in Heart Failure) trial. Methods: Patients in New York Heart Association functional class II to IV with a left ventricular ejection fraction ≤40% and elevated N-terminal pro–B-type natriuretic peptide were eligible for the DAPA-HF trial. The primary outcome in the DAPA-HF trial was the composite of an episode of worsening HF (HF hospitalization or urgent HF visit requiring intravenous therapy) or cardiovascular death. Results: Of the 4,744 patients in the DAPA-HF trial, 1,096 (23.1%) were enrolled in Asia; 721 (15.2% overall, 65.8% of patients in Asia) were enrolled in East Asia (237 in China, 343 in Japan, and 141 in Taiwan), 138 (2.9% overall, 12.6% in Asia) in South-East Asia (Vietnam), and 237 (5.0% overall, 21.6% in Asia) in South Asia (India). Patients from Asia had similar rates of worsening HF events and mortality compared with patients elsewhere. Compared with placebo, dapagliflozin reduced the risk of the primary endpoint to the same extent in patients from Asia (HR: 0.65; 95% CI: 0.49 to 0.87) as elsewhere (HR: 0.77; 95% CI: 0.66 to 0.89) (P for interaction = 0.32). Consistent benefits were observed for the other prespecified outcomes and among the regions of Asia. Study drug discontinuation and prespecified adverse events did not differ between regions. Conclusions: Dapagliflozin, compared with placebo, reduced the risk of worsening HF events and cardiovascular death to the same extent in Asian patients as elsewhere. (Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure [DAPA-HF]; NCT03036124).

Item Type:Articles
Glasgow Author(s) Enlighten ID:Docherty, Dr Kieran and Jhund, Professor Pardeep and McMurray, Professor John and Kober, Professor Lars
Authors: Docherty, K. F., Anand, I. S., Chiang, C.-E., Chopra, V. K., Desai, A. S., Kitakaze, M., Verma, S., Vinh, P. N., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Bengtsson, O., Ponikowski, P., Sabatine, M. S., Sjöstrand, M., Solomon, S. D., Langkilde, A. M., Jhund, P. S., and McMurray, J. J.V.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
Journal Name:JACC: Asia
ISSN (Online):2772-3747
Published Online:29 March 2022
Copyright Holders:Copyright © 2022 The Authors
First Published:First published in JACC: Asia 2(2): 139-153
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
303944BHF Centre of ExcellenceColin BerryBritish Heart Foundation (BHF)RE/18/6/34217CAMS - Cardiovascular Science